Trial of the Week: CHAMPION PHOENIX
Special Guest: Jack Pluenneke, PharmD, BCCP @JackPluenneke
 
Jack Pluenneke joins to discuss a March 2024 Trial of the Week, “Effect of platelet inhibition with cangrelor during PCI on ischemic events” the CHAMPION PHOENIX trial, published in 2013 in NEJM. 
We review PK/PD advantages with cangrelor, go over the CHAMPION trials, and then highlight why the CHAMPION PHOENIX trial was necessary. Then we dive into the Trial of the Week: CHAMPION PHOENIX trial and discuss its findings as well as study design. Are these patients we’d see in our ICU? How does cangrelor compare to glycoprotein 2b/3a inhibitors? Is it a weakness that the comparator group uses clopidogrel? The episode closes with medication safety considerations, cangrelor’s place in therapy, and much more.
 
Reference list:  https://pharmacytodose.files.wordpress.com/2024/03/champion-phoenix-trial-of-the-week-references-1.pdf
 
PharmacyToDose.Com
@PharmacyToDose
PharmacyToDose@Gmail.com
Learn more about your ad choices. Visit megaphone.fm/adchoices